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ABSTRACT
Exogenous insulin is, at the moment, the therapy of choice of diabetes, but does not allow
tight regulation of glucose leading to long-term complications. Recently, pancreatic islet
transplantation to reconstitute insulin-producing  cells, has emerged as an alternative
promising therapeutic approach. Unfortunately, the number of donor islets is too low
compared with the high number of patients needing a transplantation leading to a search
for renewable sources of high-quality -cells. This review, summarizes more recent
promising approaches to the generation of new -cells from embryonic stem cells for
transdifferentiation of adult cells, particularly a critical examination of the seminal work by
Lumelsky et al.THE GOAL OF therapy of type 1 diabetes (DM-1) isto restore a glycometabolic picture as close as
possible to normal. Because the cause of DM-1 is failure
to produce insulin owing to destruction of -pancreatic
ells, the therapy is replacement of lost endocrine func-
ion. Since 1921, when Nicolae Constantin Paulescu, was
ble to cure diabetes with insulin, which he called
ancreina, most patients undergo replacement therapy
ith exogenous insulin. There has been a search for a
ermanent diabetes ‘cure’ that replaces -pancreatic
cells, freeing patients from insulin requirements.
The radical solution is whole pancreas transplantation,
a surgical procedure developed in the last 10 years. It has
success rates comparable to those of other organ trans-
plantations: 80% of patients achieve and maintained
insulin independence for 6 to 8 years.1 However,
pancreas transplantation is a challenging procedure, re-
quires a significant immunosuppressive therapy to pre-
vent organ rejection,2,3 and therefore, is performed only
n combination with a kidney transplantation in diabetic
ialysis patients with end-stage renal disease.4 Unfortu-
nately, this intervention is not without complications.5
Also, xenotransplantation has received attention in the
past, but implies serious problems of health surveil-
lance.6,7 In the last few years islet transplantation has
roffered an alternative promising therapy. Recently,
xperimental approaches using stem cell administration,
ransdifferentiation of ductal cells, or genetic reprogram-
ing seem the future of diabetes therapy.
© 2013 Published by Elsevier Inc.
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General Considerations
The islets of Langerhans are clusters of endocrine cells that
constitute about 1% of pancreatic tissue where they sense
blood glucose levels, secreting hormones to regulate them.
Pancreatic islets for transplantation have been prepared by
an isolation procedure, developed by Ricordi, which com-
bines mechanical disruption and enzymatic digestion, fol-
lowed by purification through gradients of varying density
(Ricordi Chamber) (Table 1).8
The possibility to culture pancreatic islets offers a range
of therapeutic opportunities to improve efficiency and graft
survival. This procedure, which is much simpler than vas-
cularized pancreas transplantation, is associated with a low
morbidity and can be repeated to infuse additional islet
doses to achieve adequate metabolic control and insulin
independence.
The first islet transplantations performed in immunosup-
pressed patients with DM-1 were characterized by a low
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2020 GIOVIALE, BELLAVIA, DAMIANO ET ALsuccess rate, both in terms of insulin independence and
recovery of C-peptide secretion, owing to the inconsistent
quality of the transplanted islets and the inadequate immu-
nosuppression.9 The revival of this procedure occurred with
he development of an innovative immunosuppressive
cheme, the ’Edmonton Protocol’, which was applied in
elected centers worldwide to reproducibly obtain high-
uality islets.10,11 Although initial results were excellent
ith a 1-year success rate of almost 100%, continued
xperience revealed them to decrease dramatically at 2 to 3
ears. However the extraordinary initial data stimulated
esearch in the field of -cell replacement.
STEM CELLS: A SOURCE FOR NEW -CELLS
ancreatic Stem Cells
The postnatal pancreatic duct may harbor islet precursor/
stem cells because of specific cellular migration during
embryonic development.12 Islet neogenesis, the generation
of new islets from pancreatic stem/progenitor cells located
in the ducts, could be an active process in the postnatal
pancreas. Interestingly insulin-producing cells have been
generated from adult pancreatic ductal tissues in vitro.13–18
Fluorescent activated cell sorting, which characterizes hu-
man -cells through detection of CD95,19,20 may be a
romising technique to isolate multipotent pancreatic pro-
enitors from neonatal and adult pancreata. By combining
ow cytometry and clonal analysis,21,22 some authors have
described molecular markers including hepatocyte growth
factor (HGF) c-Met expressed specifically on pancreatic
stem/progenitor cells candidate. Moreover, they have iden-
Table 1. Procedure for Isolation of Pancreatic Islets
Pancreatic islet cells are obtained from multi-organ donors after
separation from the tissue surrounding the gland.
The Wirsung duct is cannulated to allow injection of a solution
containing collagenase in order to relax the organ and enable
the achievement of an effective enzyme activity during the
dissociation.
The gland is then divided into several parts and transferred to the
dissociation chamber, consisting of a lower portion, where the
pancreas is inserted together with metal balls, and an upper
portion consisting of an inverted funnel, separated by a porous
metal filter with a specific porosity.
The digestion process is the combination of the enzymatic effect
(obtained by increasing the temperature) and mechanical
(generated by the action of the ball during the stirring of the
room) that results in the release of fragments of the pancreas
that can pass through the filter metal due to the unidirectional
flow of liquid dissociation.
The digested pancreas is then purified by using different density
gradients (continuous and discontinuous) to enrich the
endocrine component.
The islets that make up only 1% of pancreatic tissue can be
viewed using a dye that gives it a distinctive red color.
After the purification, enriched fractions containing levels of purity
can be obtained.tified a new specific marker for ductal cells CD133.22 eThe use of adult stem cells isolated from patients could
solve immunologic problems associated with cell transplan-
tation. Unfortunately, adult stem cells are rare and difficult
to expand in culture. In contrast, new generation of -cells
after birth, has been reported from existing cells, and not
putative pancreatic stem cells.21 Insulin-producing -cells
have also been produced from endogenous endocrine pro-
genitors after injury.22 The existence of adult pancreatic
stem/progenitor cells and their ability to proliferate in
response to particular stimuli requires more investigations.
Stem Cells of Non-pancreatic Origin: Is Lumelsky’s
Protocol Free From Inconsistencies?
Recent studies have demonstrated that embryonic stem
cells (ESCs)23–25 induced pluripotent stem cells,26,27 and
dult stem cells from bone marrow (BM),28 pancreas,29,30
liver,31 umbilical cord blood,32 Wharton’s jelly,33 or pla-
centa,34 can differentiate into insulin-producing elements.
ecause of their high pluripotency, ESCs may be ideal for
slet regeneration; obviously, their use is under debate for
thical and legal issues as well as the risks of teratoma
ormation.35
The seminal work regarding the potentiality of ESCs to
differentiate into insulin-secreting structures similar to pan-
creatic islets was published by Lumelsky et al,23 who
bserved pancreatic islet generation from an highly en-
iched population of nestin-positive cells from embryoid
odies (EBs). EBs plated into serum-free medium showed
egative selection for all types other than nestin-positive
ells. These cells were expanded in a mitogen, basic fibro-
last growth factor, in N2 serum-free medium. Mitogen
ithdrawal thereafter promoted cessation of cell division
nd differentiation. Using reverse transcription polymerase
hain reaction (RT-PCR), the authors showed that these
SC expressed markers GATA-4 for visceral endoderm,
NF3b for definitive endoderm, as well as for pancreatic
ells, including murine insulin I, insulin II, islet amyloid
olypeptide, and the glucose transporter-2. Glucagon, a
arker for the pancreatic  cells, was also induced in the
ifferentiated cells. The acquisition of a pancreatic fate was
onfirmed by immunocytochemical analysis, which
howed many strongly insulin-positive cells by the end of
he processing.
The ability of ESC-derived islet-like cell clusters to survive
nd function in vivo was tested by grafting clusters subcutane-
usly into the shoulders of streptozotocin-diabetic mice. Im-
lanted cells were vascularized, forming aggregates mor-
hologically similar to normal pancreatic islets and
emaining immunoreactive to insulin. There was no sus-
ained correction of hyperglycemia, although the grafted
nimals maintained their body weights and survived longer
han hyperglycemic sham-grafted controls.
Boyd et al36 raised doubts about the Lumelsky protocol.
he first concern was about the interpretation of the gene
xpression data regarding the pancreatic markers. In fact,
oyd et al assert that it must be defined whether the gene
xpression was attributable to a single cell within the
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DIABETES CELL THERAPY 2021isolated cluster or whether all cells in the cluster had
transcribed the genes. Furthermore, Lumelsky’s data
showed that “insulin-producing cell clusters” (IPCCs) had a
mixed pancreatic phenotype because they contained not
only -cell but also -cell markers.
Another weakness in Lumelsky’s protocol emerged from
he quantitative PCR data,36 which demonstrated that
xpression of insulin-1 and insulin-2 mRNAs was consis-
ently higher in IPCCs obtained by Blyszczuk et al37 com-
pared with Lumelsky-generated clusters, implying that the
Blyszczuk protocol produced IPCCs with superior de novo
insulin-producing activity. The amylase-2 expression in
IPCCs obtained by other groups following Lumelsky’s
protocol38 suggested that it may also promote exocrine
differentiation; evidence not in favor of a unique -cell
phenotype acquired by ESCs. Using immunofluorescence,
Rajagopal et al39 observed an attenuated relative ratio of
C-peptide to insulin, suggesting that the insulin content by
IPCCs was an unequal combination of de novo synthesis
and adsorption from the culture medium. Most notably,
however, the Blyszczuk protocol37 consistently produced
he highest level of C-peptide, indicating that it achieved
uperior de novo insulin synthesis. Furthermore, cell clus-
ers obtained by Lumelsky and Blyszczuk showed promi-
ent glucagon costaining with insulin,36 indicating that the
IPCCs derived from ESCs may not represent surrogate
-cells but rather more closely resemble an  and  cell
hybrid Boyd et al40 proposed that glucagon/insulin costain-
ing could alternatively indicate that IPCCs derived from
ESCs were developmentally immature endocrine cells as
suggested by the high expression of neurogenin-3 which,
instead, is downregulated in fully mature islets. Further-
more, IPCCs seem to be defective in glucose-sensing capac-
ity in vivo, supported by glucose stimulation assays that
showed that IPCC insulin released in response to minimal
glucose stimulation (3.3 mmol/L glucose) but not signifi-
cantly by greater glucose stimulation (25 mmol/L glucose).
In light of these issues, it seems that ESCs-based strategies
to obtain pancreatic islet-like cells require further investi-
gation.
Mesenchymal Stem Cells From Adipose Tissue or
Umbilical Cord: Is It a Valid Alternative to ESCs?
An alternative to ESCs could be adipose-derived stem cells
(ADSCs) because of their abundance, availability and possi-
bility for autologous use.41 Three research groups have shown
hat under specific culture conditions, ADSCs differentiate
nto insulin, somatostatin, and glucagon-expressing or C-
eptide positive cells.42,43 Packing these cells into immunoiso-
lation capsules to test their in vivo/in vitro functionality,
Chandra et al44 reported their ability to restore normoglyce-
ic conditions in streptozotocin-induced diabetic mice. Inter-
stingly for the first time, this study showed that undifferenti-
ted ADSCs exerted moderate control of blood glucose levels,
eading to the speculation that the autocrine and paracrine
actors of a regenerating pancreas and an hyperglycemic local
iabetic micro-environment can contribute to ADSC differen- diation. This phenomenon has also been shown for bone
arrow-derived stem cells.45
Islet neogenesis has also been reported from constitu-
tively nestin-expressing human umbilical cord matrix-
derived mesenchymal stem cells. Kadam et al46 reported
that human placenta-derived mesenchymal stem cells
(hPDMSCs) could differentiate into islet-like cells able to
restore normoglycemia when transplanted under the kidney
capsules of streptozotocin-induced diabetic mice. Interest-
ingly unlike human cord blood or amnion-derived mesen-
chymal stem cells, the gene expression profile of undiffer-
entiated hPDMSCs showed that they expressed mRNA for
insulin, glucagon, somatostatin, Ngn3, and Isl1.
Cooperation Between -Cells and Bone Marrow: Stem
ells as a Support for Islet Function and Regeneration
Vascularization of pancreatic islets is important for their
ability to secrete insulin. Obviously, islet isolation47 breaks
vascularization, which can compromise irremediably the
endocrine function; a preservation method needs to coun-
teract this deleterious effect.48,49 Endothelial cells deliver
xygen and nutrients to endocrine cells, contributing to
reate a microenvironment for -cell function. In particu-
lar, they can induce insulin gene expression during islet
development, stimulate -cell proliferation, and produce a
number of vasoactive, angiogenic substances, and growth
factors.50–52
Hematopoietic stem cells, mesenchymal stem cells, and
endothelial progenitor cells contribute to islet revasculariza-
tion through vessel formation by differentiation into mature
endothelial cells (EPCs) or release of pro-angiogenic factors
such as HGF and vascular endothelial growth factor
A.53–55 In this regard, Mathew et al56 provided evidence
hat bone marrow-derived EPCs, transplanted after a
ancreatic injury migrate to the site of damage helping
njured -cells to recover even if they did not differenti-
te into insulin-producing cells.
Two other papers stress the synergism between -cells
nd BM-derived cells. Sakata et al57 showed that only a
ombined transplantation under the kidney capsule of total
M-derived cells (not only the mesenchymal cellular frac-
ion) with islets was able to significantly lower blood glucose
evels in a streptozotocin-induced diabetes murine model.
nterestingly BM-cell transplantation alone did not produce
ormoglycemic mice or insulin-positive cells, suggesting
hat direct differentiation of BM cells into -cells was
unlikely. Ito et al58 provided similar evidence but in this
case the site of combined BM cells/islet transplantation was
the liver not the kidney. BM-derived stem cells may also
have a role to stimulate -cell regeneration.59–61 For
xample, infusion of mesenchymal stem cells into NOD/
CID mice increased the number of endogenous -cells
mproving hyperglycemia after streptozocin-induced islet
estruction.
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2022 GIOVIALE, BELLAVIA, DAMIANO ET ALBEYOND STEM CELL-BASED THERAPY:
TRANSDIFFERENTIATION OF ADULT CELLS TOWARD
AN ISLET-LIKE PHENOTYPE
Biologic Premises
Pancreas development begins with dorsal and ventral
protrusions of the primitive gut epithelium that fuse later
to form the definitive organ characterized by the appear-
ance of glucagon-producing cells. Thereafter a few insulin-
producing cells appear, often co-expressing glucagon. A
later step consists of a peak of endocrine cell genesis
leading to numerous fully differentiated insulin-expressing
-cells and glucagon-producing -cells. At the end of
pancreas development, endocrine cells begin to form well-
organized islets of Langerhans.
The mechanisms responsible for the development of
these endocrine cell types are not fully understood, but
experiments consisting of generation of mice deficient for a
number of pancreatic transcription factors have helped to
shed more light about them by identifying crucial mediators
of organ development: Sox9, Pdx1, Ngn3, IA1, Pax4, Arx,
Nkx2.2, Nkx6.1, Nkx6.2, Pax6, and MafA.62
Transdifferentiation Achieved by Genetic Reprogramming
Using Transcription Factors Carrying Vectors
All pancreatic cells derive from Pdx1-expressing progeni-
tors,63 the basis of experiments to obtain pancreatic ele-
ments from other cell types.64–66 In all of these cases,
adenoviral-mediated misexpression of Pdx1 in mouse liver
prevented streptozotocin-induced hyperglycemia in animal
models. Kaneto et al67 showed that concomitant adenoviral
pplication of 2 factors, Pdx1 and Ngn3 or NeuroD in the
ivers of mice produced transdifferentiation of hepatic cells
nto insulin-producing elements associated with significant
melioration of glucose tolerance.
Transdifferentiation Achieved Modifying Cellular Micro-
environment In Vitro
Intriguingly, exocrine pancreatic cells have the capacity to
generate their endocrine counterparts when exposed in
vitro to a particular microenvironment, consisting of epi-
dermal growth factor and leukemia inhibitory factor, ago-
nists of the JAK2/STAT3 signalling pathway.68 We have
reported our own experience in a porcine model concerning
the isolation by surgical microdissection of Wirsung duct
cells that, upon in vitro exposure to glucose, acquired the
ability to secrete insulin and glucagon.18 Finally, it seems
note worthy that human monocytes treated with macro-
phage colony-stimulating factor and interleukin 3 transdif-
ferentiated into pancreatic islet-like cells in a glucose-
dependent manner.69
In conclusion, regenerative medicine has undergone
great development in the last few years. Due to its enor-
mous social and economic implications, diabetes cell ther-
apy is among the most investigated branches of this field.
Islet transplantation has shown significant limitations. Al-
ternative approaches based on a full knowledge of cellularnd developmental biology of pancreatic cells have been
nder investigation. Transdifferentiation, the process that
eads an adult cell to change its phenotype, seems to be a
romising approach given that adult cells are autologous,
ot dangerous or potentially tumorigenic, and free of the
thical implications associated with embryonic stem cells.
The transfer of the experimental results on experimental
pproach to increase availability of -cells to the clinic still
eems distent.
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